Dr Lal Pathlabs Ltd
NSE: LALPATHLAB · Healthcare Service Provider
Snapshot
Unlock Dr Lal Pathlabs Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Dr. Lal PathLabs Limited is a prominent Indian healthcare service provider specialising in diagnostic and pathological testing services. The company operates an extensive network of clinical laboratories, patient service centres, and pick-up points to deliver comprehensive diagnostic solutions.
Business Model
The company generates revenue by providing a wide range of diagnostic tests including biochemistry, haematology, and microbiology. It operates through a hub-and-spoke model, leveraging a central reference laboratory supported by regional labs and a vast network of collection points.
- Clinical Laboratories:277
- Patient Service Centres:4,731
- Pick-up Points:10,599
Growth Outlook
Growth is driven by the expansion of the diagnostic network and the increasing demand for specialised pathological investigations. The company continues to focus on scaling its reach across India to capture a larger share of the organised diagnostic market.
Key Risks
- Intense Market Competition. The diagnostic sector in India is highly fragmented with significant competition from both organised chains and local unorganised players.
- Regulatory Compliance. Changes in healthcare regulations or pricing caps on diagnostic tests could adversely impact profit margins.
- Operational Risks. Maintaining consistent quality standards across a vast, geographically dispersed network of laboratories and collection centres is critical to brand reputation.
- Technological Disruption. Failure to adopt emerging diagnostic technologies or digital health platforms may lead to a loss of market share to tech-enabled competitors.
Start your research today
Unlock AI insights, financials, peers and live data on Dr Lal Pathlabs Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,891 Cr
TTM · consolidated
NET PROFIT
₹546 Cr
TTM · consolidated
EPS
₹41.48
TTM · consolidated
RETURN ON EQUITY
23.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
29.6%
TTM · consolidated
P/E
48.3×
Q1 FY27 · consolidated
EV/EBITDA
34.0x
Q1 FY27 · consolidated
EBITDA MARGIN
32.6%
TTM · consolidated
NET PROFIT MARGIN
21.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Service Provider
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Dr Lal Pathlabs LtdLALPATHLAB | ₹32,259 Cr | 48.3× | 33.96 | 14.3% | 32.6% | 23.3% | 29.6% | -36.7% |
Vijaya Diagnostic Centre Ltd.VIJAYA | ₹16,162 Cr | 78.3× | 41.96 | 20.2% | 44.8% | 21.4% | 23.1% | +42.3% |
Metropolis Healthcare Ltd.METROPOLIS | ₹12,139 Cr | 23.0× | 27.17 | 21.8% | 26.0% | 14.3% | 17.8% | -73.6% |
Thyrocare Technologies Ltd.THYROCARE | ₹9,132 Cr | 31.2× | 30.51 | 21.1% | 34.0% | 31.1% | 38.4% | -53.6% |
Nephrocare Health ServicesNEPHROPLUS | ₹7,444 Cr | — | — | — | 23.0% | — | — | — |
Suraksha Diagnostic Ltd.SURAKSHA | ₹1,851 Cr | 50.0× | 17.47 | 22.5% | 32.7% | 15.8% | 18.6% | +17.7% |
As of Q1 FY27
Financials
Dr Lal Pathlabs Ltd
NSE: LALPATHLAB · Healthcare Service Provider
Snapshot
Unlock Dr Lal Pathlabs Ltd's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Dr. Lal PathLabs Limited is a prominent Indian healthcare service provider specialising in diagnostic and pathological testing services. The company operates an extensive network of clinical laboratories, patient service centres, and pick-up points to deliver comprehensive diagnostic solutions.
Business Model
The company generates revenue by providing a wide range of diagnostic tests including biochemistry, haematology, and microbiology. It operates through a hub-and-spoke model, leveraging a central reference laboratory supported by regional labs and a vast network of collection points.
- Clinical Laboratories:277
- Patient Service Centres:4,731
- Pick-up Points:10,599
Growth Outlook
Growth is driven by the expansion of the diagnostic network and the increasing demand for specialised pathological investigations. The company continues to focus on scaling its reach across India to capture a larger share of the organised diagnostic market.
Key Risks
- Intense Market Competition. The diagnostic sector in India is highly fragmented with significant competition from both organised chains and local unorganised players.
- Regulatory Compliance. Changes in healthcare regulations or pricing caps on diagnostic tests could adversely impact profit margins.
- Operational Risks. Maintaining consistent quality standards across a vast, geographically dispersed network of laboratories and collection centres is critical to brand reputation.
- Technological Disruption. Failure to adopt emerging diagnostic technologies or digital health platforms may lead to a loss of market share to tech-enabled competitors.
Start your research today
Unlock AI insights, financials, peers and live data on Dr Lal Pathlabs Ltd and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,891 Cr
TTM · consolidated
NET PROFIT
₹546 Cr
TTM · consolidated
EPS
₹41.48
TTM · consolidated
RETURN ON EQUITY
23.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
29.6%
TTM · consolidated
P/E
48.3x
Q1 FY27 · consolidated
EV/EBITDA
34.0x
Q1 FY27 · consolidated
EBITDA MARGIN
32.6%
TTM · consolidated
NET PROFIT MARGIN
21.4%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Service Provider
As of Q1 FY27